HCV Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: the SToP-C Study

The SToP-C study results were presented at the International Liver Congress, held in London, UK on 22-26 June 2022.

The aim of the study was to assess incidence and risk of HCV reinfection following rapid scale up of direct-acting antiviral therapy in four Australian prisons, where opioid agonist therapy was available, but not needle and syringe programs.

More details about the study are available here.